Adaptimmune Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.04.17	Gainers & Losers Of Apr.6: HTGM, AKTX, FGEN, ARLZ, ADAP... (RTTNews)
05.12.16	Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study (GlobeNewswire)
10.11.16	Adaptimmune Reports Third Quarter 2016 Financial Results (GlobeNewswire)
27.10.16	Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma (GlobeNewswire)
26.09.16	MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers (GlobeNewswire)
08.08.16	Adaptimmune Reports Second Quarter 2016 Financial Results (GlobeNewswire)
03.08.16	Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma (GlobeNewswire)
28.07.16	Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma (GlobeNewswire)
26.07.16	Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma (GlobeNewswire)
21.06.16	Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System (GlobeNewswire)
20.06.16	Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR(TM) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma (GlobeNewswire)
12.05.16	Adaptimmune Reports First Quarter 2016 Financial Results (GlobeNewswire)
07.04.16	Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer (GlobeNewswire)
17.03.16	Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015 (GlobeNewswire)
09.02.16	U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune's Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma (GlobeNewswire)
02.02.16	Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration (GlobeNewswire)
22.01.16	Adaptimmune Announces New Additions to Manufacturing Senior Management (GlobeNewswire)
17.12.15	Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer (GlobeNewswire)
01.12.15	Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies (GlobeNewswire)
24.11.15	Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer (GlobeNewswire)
13.11.15	Adaptimmune Reports First Quarter Financial Results for Fiscal Year 2015-16 (GlobeNewswire)
05.11.15	Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC) (GlobeNewswire)
13.10.15	Adaptimmune Reports Full Fiscal Year 2015 Financial Results (GlobeNewswire)
07.10.15	Adaptimmune to Report Full Fiscal Year 2015 Financial Results on October 13, 2015 (GlobeNewswire)
06.10.15	Adaptimmune Announces New Research and Development Facility in Oxfordshire (GlobeNewswire)
01.09.15	Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma and Achieves Clinical Milestones (GlobeNewswire)
20.07.15	Adaptimmune's NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients (GlobeNewswire)
02.07.15	Adaptimmune: FDA Accepts IND For MAGE-A10 T - Quick Facts (RTTNews)
02.07.15	Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients With Non-Small Cell Lung Cancer (GlobeNewswire)
30.05.15	Adaptimmune Announces Data From Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting (GlobeNewswire)
20.05.15	Adaptimmune Announces New Additions to Senior Clinical Management (GlobeNewswire)
11.05.15	Adaptimmune Announces Closing of Initial Public Offering (GlobeNewswire)
06.05.15	Adaptimmune Announces Pricing of Initial Public Offering (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	97.11	1.59 %	K V
Roche Hldg G	289.30	1.15 %	K V
Givaudan	3’946.00	0.87 %	K V
Swiss Life Hldg	747.80	0.86 %	K V
Alcon	83.50	0.85 %	K V
Geberit	503.00	-0.04 %	K V
Nestle	77.24	-0.28 %	K V
Sika	226.90	-0.57 %	K V
ABB	48.96	-0.79 %	K V
UBS Group	29.30	-0.85 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Adaptimmune Therapeutics PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten